

**FARIBA AHMADIZAR, PharmD, MSc, PhD**

Department of Epidemiology

Erasmus University Medical Center

Dr. Molewaterplein 50, Office NA27-10, PO Box 2040, 3000 CA

Rotterdam, the Netherlands.

Tel: +31-343410654

Mobile phone: 0645781270

Email: [f.ahmadizar@erasmusmc.nl](mailto:f.ahmadizar@erasmusmc.nl)

---

**Qualifications:**

- Doctorate in Pharmacy (PharmD), Shahid Beheshti University of Medical Science, 1992-1998
- Ph.D. in Pharmacoepidemiology, Utrecht University, 2012-2016
- MSc in Epidemiology, University Medical Center Utrecht, 2016-2017

**Current appointments:**

- Postdoctoral Research Fellow, Department of Epidemiology, Erasmus MC, Rotterdam, since May 2017
- Visiting professor of Pharmacoepidemiology, Shiraz University of Medical Science, Iran, since April 2018

**Current research grants:**

- Stratification of Obese Phenotypes to Optimize Future Obesity Therapy (SOPHIA), IMI grant, *Co-applicant*, 9 million€, 2020 (Erasmus MC: 300k€, 3 years Posdoc appointment for data management/analyses).
- Comparative Effectiveness Study on GLP1-Ras in Patients with T2D, *Main applicant*, 100k€, 2019

**Previous relevant research grants:**

- Mining treatment in patients with type 2 diabetes, *Main applicant*, 30k€, 2017
- Medication treatment policy in patients with non-communicable disorders, *Co-applicant*, 90k€, 2018

**Awards and honors:**

- Scholarship from the exceptional talents at Iranian Ministry Of Health; an exclusive honor to study Ph.D. abroad, 2012.
- Graduating from Pharmacy school with great honor (Cum Laude), 1998.

**Work experience:**

- An employee in the Ministry of Health, Iran, 1999-2012.
- Director of Rational Use of Drug, Food and Drug Administration, Iran, 2011-2012.

### Scientific Collaborations:

- An active member of the CHARGE, COMBI-BIO, BBMRI-NL, NCD-RisC Consortia; mainly working on cardiometabolic disorders.
- Collaboration with Universities inside (UMC Groningen, UMC Leiden, UMC Utrecht) and outside the Netherlands (Harvard, Imperial College London, Steno Diabetes Center in Denmark, ISPM in Switzerland).
- An active member of the European Association of the Study of Diabetes (EASD), and the International Society for Pharmacoepidemiology (ISPE).
- Closely engagement with journals; editorial board member in Frontiers in Pharmacology, an active reviewer in EJPC, Diabetes, Metabolic Syndrome and Obesity journal, Lancet endocrinology, and JAMA.

### Scientific achievements:

- Building up a PARKER Consortium to study on “Prediabetes trajectories of biomarkers”
- Building up a hub for Cochrane diabetes and metabolic disorders in the Netherlands

### Thesis supervised (as ‘Co-promotor’):

1. Marianna Mirtaza, MSc (pharmacogenetic association of IL1RL1 variants with asthma severity in Dutch children under ICSs treatment, 2016)
2. Maurits Roos, MSc (Micro and macrovascular complications across the glycemic spectrum, 2020)
3. Kan Wang, MSc, Ph.D. (Epidemiology of type 2 diabetes, expected 2022)
4. Negin Soroush, MSc, Ph.D. (Pharmacogenetic of cardiometabolic disorders, expected 2023)
5. Fereshteh Shokri, MSc, Ph.D. (Gut microbiome and type 2 diabetes, expected 2024)
6. Mitra Nekoie, MD, Internship (Psychiatric medication in the diabetic population, expected 2021)
7. Soroush Mohammadi, MSc, Internship (Pharmacogenetic of diabetogenic medications, expected 2021)

### Teaching Experience:

- Lecturer in Pharmacoepidemiology and Diabetes Epidemiology courses at NIHES, since 2018 September.
- Lecturer in study design, introduction to pharmacoepidemiology, systematic review, and meta-analysis courses, in the virtual platform of Edinburgh University, since 2020 April.
- Established academic post-graduate training for **Low** and **Middle-Income Countries** known as LoMIC-P4; **Pharmacoepidemiology & Pharmacovigilance**, **Pharmacogenetics**, and **Pharmacoeconomy**, with a virtual platform that leads to an MPH degree, since 2020 February.

### Publications:

#### Books

- 1- **F. Ahmadizar**, N. Khoshnevis, 2010, “*Practical Information in Pharmacy for pharmacists*”, N. Hadavand, Z. Jahangard, pp.168, Hayyan, Tehran.

- 2- F. Soleymani, **F. Ahmadizar**, F. Fahimi, 2009, “*Drug and Therapeutic Committee*”, F. Roshanzamir, M. Naseri, pp. 252, Andishe mandegar, Tehran.
- 3- N. Mohammadhoseyni, F. Soleymani, N. Sodaeejahromi, **F. Ahmadizar**, 2008, “*The amazing world of bacteria*”, pp. 54, Andishe mandegar, Tehran.

#### **Journal articles: Submitted/Accepted/Published**

**Fariba Ahmadizar**, Petra Czarniak, Jeff Hughes, Richard Parsons, Bruno Stricker. *Association of proton pump inhibitors and incident type 2 diabetes*. Submitted.

Negin Soroush, Alex Aarnoudse, Maryam Kavousi, Jan Kors, **Fariba Ahmadizar**, Bruno Stricker. *A NOS1AP gene variant modifies the risk of sudden cardiac death in users of digoxin*. Submitted.

**Fariba Ahmadizar**, Kan Wang, Alis Heshmatollah, M. Arfan Ikram, M. Kamran Ikram, Maryam Kavousi. *Lifetime risk of cardiovascular disease across the glycaemic spectrum among women and men from the general population*. Submitted.

Kan Wang, Maryam Kavousi, Trudy Vortman, M. Arfan Ikram, **Fariba Ahmadizar**. *Cardiovascular health, genetic predisposition, and lifetime risk of type 2 diabetes in the general population*. Submitted.

Symen Ligthart, **Fariba Ahmadizar**, Thijs T.W. van Herpt, Maarten J.G. Leening, André G. Uitterlinden, Eric J.G. Sijbrands, Oscar H. Franco, Abbas Dehghan. *Genetic susceptibility, body mass index, and lifetime risk of type 2 diabetes: a prospective cohort study*. Submitted.

Noor E. Taams, **Fariba Ahmadizar**, Rens Hanewinkel, Judith Drenthen, M. Arfan Ikram, Maryam Kavousi, Pieter A. van Doorn. *Cardiovascular health score and chronic axonal polyneuropathy: a population-based cohort study*. Submitted.

Elif Aribas, **Fariba Ahmadizar**, Unal Mutlu, M. Kamran Ikram, Jannine Roeters van Lennep, Maryam Kavousi. *Associations between Sex Hormones and Markers of Micro- and Macrovascular damage among Women and Men from General Population*. Submitted.

Fereshteh Shokri, Marlies Mulder, Annelies Verbon, Bruno Stricker, **Fariba Ahmadizar**. *Bi-directional interactions between glucose-lowering medication and gut microbiome in patients with type 2 diabetes mellitus. A Review*. Submitted.

Peyman Nowrouzi-Sohrabi, Reza Tabrizi, Negin Soroush, Mandy van Hoek, **Fariba Ahmadizar**. *Cardiometabolic risk profile associated with Liraglutide treatment in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials*. Submitted.

Elif Aribas, Jeanine E. Roeters van Lennep, Suzette E. Elias-Smale, Jan J. Piek, Maurits Roos, **Fariba Ahmadizar**, Banafsheh Arshi, Dirk J. Duncker, Yolande Appelman, Maryam Kavousi. *Prevalence of coronary microvascular dysfunction among patients with symptoms in the absence of obstructive coronary artery disease: a systematic review*. Submitted.

Joëlle E. Vergroesen, Bruno Stricker, M. Arfan Ikram, **Fariba Ahmadizar**, Maryam Kavousi, Albert Hofman, et al. *Systemic use of metformin decreases the risk of open-angle glaucoma*. Submitted.

**Fariba Ahmadizar**, Adela Brahimaj, Meike W. Vernooij, M. Kamran Ikram, M. Arfan Ikram, Daniel Bos, Maryam Kavousi. *Epicardial Fat Volume and the Risk of Cardio-metabolic Diseases among Women and Men from the General Population*. Accepted by European Endocrinology Journal. 2020.

Marziyeh Zare, Saba Afifi, Iman Karimzadeh, Kamran B. Lankarani, Ali Mohammad Sabzghabae, **Fariba Ahmadizar**, Payam Peymani. *A Population-Based Study on Patients Complaining Regarding Community Pharmacies Services*. Accepted by JRPP. 2020.

**Fariba Ahmadizar**, Bruno Stricker. *Response to 'comment on "associations of statin use with glycemic traits and incident type 2 diabetes*. 2020 May 22. Br J Clin Pharmacol. 2020;10.1111/bcp.14323.

Sulmaz Ghahramani, Reza Tabrizi, Kamran B Lankarani, **Fariba Ahmadizar**. *Laboratory features in severe vs. non-severe COVID-19 patients, a systematic review and meta-analysis*. Research Square. May 2020.

Tofte N, Vogelzangs N, Mook-Kanamori D, **Fariba Ahmadizar**, et al. *Plasma metabolomics identifies markers of impaired renal function: A meta-analysis of 3,089 persons with type 2 diabetes*. J Clin Endocrinol Metab. 2020; dgaa173.

**Fariba Ahmadizar**, Maryam Kavousi, Pim van der Harst. *Heritability analyses of resting heart rate: Is it relevant?* Eur J Prev Cardiol. 2020.

J. Maurik van den Heuvel, Niloufar Farzan, Mandy van Hoek, Anke H. Maitland-van der Zee, **Fariba Ahmadizar**. *Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands*. BMJ Open Diabetes Research and Care 2020; 8:e000767

Maryam Akbari, Bahareh Kardeh, Reza Tabrizi, **Fariba Ahmadizar**, Kamran B Lankarani. *Incidence rate of gastric cancer adenocarcinoma in patients with gastric dysplasia. A Systematic Review and Meta-Analysis*. J Clin Gastroenterol. 2019 Nov/Dec;53(10):703-710.

**Fariba Ahmadizar**, Carolina Ochoa-Rosales, Marija Glisic, Oscar H. Franco, Taulant Muka, Bruno H. Ch. Stricker. *Associations of statin use with glycemic traits and incident type 2 diabetes*. Br J Clin Pharmacol. 2019 March 5.

Reza Tabrizi, Omid Reza Tamtaji, Naghmeh Mirhosseini, Kamran B Lankarani, Maryam Akbari, Ehsan Dadgostar, Afshin Borhani-Haghighi, Payam Peymani, **Fariba Ahmadizar**, Zatollah Asemi. *The effects of statin therapy on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials*. Pharmacology research Journal. 2019 March: 85-103.

Marija Glisic, Natyre Kastrati, Valentina Gonzalez, Wichor M. Bramer, **Fariba Ahmadizar**, Rajiv Chowdhury, Jan Danser, Anton Roks, Trudy Voortman, Oscar H. Franco, Taulant Muka. *Association between phytoestrogens, glucose homeostasis and risk of type 2 diabetes in women: a systematic review and meta-analysis*. Adv Nutr. 2018 Nov 1;9(6):726-740.

Amin Hassanvand, **Fariba Ahmadizar**, Abbaszadeh, A., Amini-Khoei, H., Goudarzi, M., Abbasnezhad, A., et al. *The Antinociceptive Effects of Rosuvastatin in Chronic Constriction Injury Model of Male Rats*. Basic and Clinical Neuroscience. 2018. 9(4), 251-260

Hasanvand, A., Pirzadroozbahani, N., **Fariba Ahmadizar**., Kharazmkia A., Mir, S., Baharvand, P., Goudarzi, M., Khorramabadi, R. *Evaluation of the antioxidant effects of zolpidem in the rat model of cisplatin-induced nephrotoxicity*. Journal of renal injury prevention. 2018, 7 (4). pp. 235-239

Z. Karimian; M. Kheirandish; N. Javidnikoo; G. Asghari; **Fariba Ahmadizar**; R. Dinarvand. *Adverse Drug Reactions in relation with Medication Errors in Iran (2015-2017): A P-Method Approach*. ijhpm.2018.

Amin Hassanvand, **Fariba Ahmadizar**. *Metformin and prevention of diabetic kidney disease*. J. Nephrothol. 2018, 7 (x):x-x.

**Fariba Ahmadizar**, Anke H. Maitland-van der Zee. *AddIT Editorial comment- Challenges in Medication Treatment of Renal and Cardiovascular diseases and Risk Factors in Adolescents with Type 1 diabetes*. Annals of Translational Medicine. 2018.03.25.

**Fariba Ahmadizar**, Trudy Voortman. *Editorial comment- Arterial Stiffness in Childhood. A predictor for later cardiovascular disease?*. Eur J Prev Cardiol. 2018; 25(1):100-102.

**Fariba Ahmadizar**, Patrick Souverein, Anthonius de Boer, Anke H. Maitland-van der Zee. *Under-treatment of hypertension and hypercholesterolemia in children and adolescents with type 1 diabetes- Long term follow-up on time trends in the occurrence of cardiovascular disease, risk factors, and medications use*. Br J Clin Pharmacol. 2017 December.

Ali Arabkhazaeli, **Fariba Ahmadizar**, Susanne J. H. Vijverberg, Maarten Leusink, Hubertus G. M. Arets, Jan A.M. Raaijmakers, Cuno S. Uiterwaal, Cornelis K. van der Ent, Anke-Hilse Maitland-van der Zee. *Association of Allergy genetic risk score with allergies in children- Wheezing illnesses study Leidsche Rijn cohort*. Pediatr Allergy Immunol. 2017 Oct 19.

**Fariba Ahmadizar**, Susanne J. H. Vijverberg, Hubertus G. M. Arets, Anthonius de Boer, Jason E. Lang, Johan Garssen, Aletta Kraneveld, Anke H. Maitland-van der Zee. *Early life antibiotics exposure increases the risk of developing allergic symptoms later in life: A meta-analysis*. Allergy. 2017; 00:1-16.

**Fariba Ahmadizar**, Susanne J. H. Vijverberg, Hubertus G. M. Arets, Anthonius de Boer, Johan Garssen, Aletta D. Kraneveld, Anke H. Maitland-van der Zee. *Breastfeeding is associated with a decreased risk of asthma exacerbations later in life*. Pediatr Allergy Immunol. 2017 Jul 29.

**Fariba Ahmadizar**, Susanne J. H. Vijverberg, Hubertus G. M. Arets, Anthonius de Boer, Steve Turner, Graham Devereux, Ali Arabkhazaeli, Patricia Soares, Somnath Mukhopadhyay, Johan Garssen, Colin N.A. Palmer, Liesbeth Duijts, Evelien R. van Meel, Aletta D. Kraneveld, Anke H. Maitland-van der Zee. *Use of antibiotics in early childhood and the risk of asthma onset/asthma exacerbations*. *Pediatr Allergy Immunol*. 2017 Apr 19.

**Fariba Ahmadizar**, Susanne J. H. Vijverberg, Hubertus G. M. Arets, Anthonius de Boer, Jason E. Lang, Meyer Kattan, Colin N.A. Palmer, Somnath Mukhopadhyay, Steve Turner, Anke H. Maitland-van der Zee. *Childhood obesity in relation to poor asthma control and exacerbations- A meta-analysis*. *Eur Respir J*. 2016, Sep; 1-11.

**Fariba Ahmadizar**, Patrick C. Souverein, Hubertus G. M. Arets, Anthonius de Boer, Anke H. Maitland-van der Zee. *Asthma-related medication use and exacerbations in children and adolescents with type 1 diabetes*. *Pediatr pulmonol*. 2016 May; 1-9.

**Fariba Ahmadizar**, Susanne J. H. Vijverberg, Hubertus G. M. Arets, Anthonius de Boer, Jason E. Lang, Johan Garssen, Aletta Kraneveld, Anke H. Maitland-van der Zee. *Early-life antibiotic exposure is associated with an increased risk of allergy*. *European Respiratory Journal*. 2016.

**Fariba Ahmadizar**, Soulmaz Fazeli Farsani, Patrick C. Souverein, Marja M. J. van der Vorst, Anthonius de Boer, Anke H. Maitland-van der Zee. *Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort stud*. *Pediatr diabetes*. 2015 Aug; 17(6): 433-40.

**Fariba Ahmadizar**, N.Charlotte Onland-Moret, Anthonius de Boer, Geoffrey Liu, Anke H. Maitland-van der Zee. *Efficacy and safety assessment of the addition of bevacizumab to adjuvant therapy agents in cancer patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials*. *PLoS One*. 2015 Sep; 2;10 (9).

Fatemeh Soleymani, **Fariba Ahmadizar**, Alipasha Meysamie, Mohammad Abdollahi. *A survey on the factors influencing the pattern of medicine's use: Concerns on irrational use of drugs*. *J Res Pharm Pract*. 2013; 2 (2):59-63.

Nasrin Khoshnevis **Fariba Ahmadizar**, Mahtab Alizadeh, Mohammad Esmail Akbari. *Nutritional Assessment of Cancer Patients in Tehran, Iran*. *Asian Pac J Cancer Prev*. 2012; 13(4):1621-6.

**Fariba Ahmadizar**, Fatemeh Soleymani, Mohammad Abdollahi. *Study of Drug-Drug Interactions in Prescriptions of General Practitioners and Specialists in Iran 2007-2009*. *Iran J Pharm Res*. 2011;10 (4):921-31.

## Conferences (oral/poster presentation-invited speakers)

- Metabolomics signature of Epicardial fat, **Health-RAI** 2020, Utrecht, the Netherlands.
- Micro and macrovascular disorders and incident type 2 diabetes, A Mendelian Randomization Approach. **ADDRM** 2019, Wageningen, the Netherlands.
- Statin use and metabolic syndrome. **WEON** 2019, Groningen, the Netherlands.
- Multi-omics data and their applications in Pharmacoepidemiology. **EAPEC** 2019, Tehran, Iran.
- Statin use is associated with increased levels of glycemic traits and increased risk of incident type 2 diabetes. **ICPE** 2018, Prague, the Czech Republic.
- Strategic plans to conduct pharmacoepidemiological studies in Iran. **EAPEC** 2018, Shiraz, Iran.
- Pharmacoepidemiology in the Netherlands- Focusing on antibiotic use in the pediatric population. **EAPEC** 2018, Shiraz, Iran.
- Early life antibiotics exposure and the risk of developing asthma/asthma exacerbations later in life. **ICPE** 2017, Montreal, Canada.
- Under-treatment of hypertension and hypercholesterolemia in children and adolescents with type 1 diabetes. **ICPE** 2017, Montreal, Canada.
- Early life antibiotics exposure increases the risk of developing allergic symptoms later in life: A meta-analysis. **ERS** 2016, London, the UK.
- Childhood obesity in relation to poor asthma control and exacerbations- A meta-analysis. **ICPE** 2016, Dublin, Ireland.
- Early life antibiotics exposure increases the risk of developing allergic symptoms later in life: A meta-analysis. **ICPE** 2016, Dublin, Ireland.
- Childhood obesity in relation to poor asthma control and exacerbations- A meta-analysis. **ERS** 2016, London, the UK.
- Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study. **ICPE** 2015, Boston, the USA.
- Asthma-related medication use and exacerbations in children and adolescents with type 1 diabetes. **ICPE** 2015, Boston, the USA.
- Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study. **FIGON** 2014, the Netherlands.
- Study of Drug-Drug Interactions in Prescriptions of General Practitioners and Specialists in Iran 2007-2009. **EAHP** 2011, Vienna, Austria.
- Drug Usage Pattern in over 60-year-old population in Tehran in 2007. **ISPOR** 2010, **Thailand**.

## Interview:

New York Times (2019), Huffington Post and Reuters (2016); presenting the results of my studies

## Language:

English and Dutch (intermediate)